Idenix $2.5bn ruling will impede innovation, says Amgen
04-02-2020
Merck suffers blow as $2.5bn Gilead fine overturned
19-02-2018
tzahiV / iStockphoto.com
Biopharmaceutical company Gilead has escaped a finding of enhanced damages in its patent dispute with Idenix Pharmaceuticals, a subsidiary of Merck.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Gilead, Merck, Idenix, patent, Sovaldi, Harvoni, damages, patent infringement, enhanced damages, hepatitis C
